Are Olumiant and Hadlima the Same Thing?
Olumiant(baricitinib) andHadlima(adalimumab-bwwd) are used to treatrheumatoid arthritis(RA).
Hadlimais also used to treatjuvenileidiopathicarthritis(JIA),psoriatic arthritis(PsA),ankylosing spondylitis(AS), adultCrohn's disease(CD),ulcerative colitis(UC), andplaque psoriasis(Ps).
Hadlimais biosimilar to Olumiant (adalimumab).
Hadlimaand Olumiant belong to different drug classes. Hadlima is atumor necrosis factor(TNF) blocker and Olumiant is a Janus kinase (JAK) inhibitor.
Side effectsof Olumiant that are different from Hadlima includenausea, cold sores (herpessimplex), andshingles(herpes zoster).
Side effects of Olumiant and Hadlima that are similar include infections (e.g. upperrespiratorytract,sinusitis).
Side effects of Hadlima that are different from Olumiant include injection site reactions (redness,itching, bleeding,pain, and swelling),headache, andrash.
Both Hadlima and Olumiant may interact with abatacept, anakinra,cyclosporine,生活vaccines.
Olumiant may also interact withmethotrexate, probenecid, steroids,aspirinor other nonsteroidalanti-inflammatory drugs (NSAIDs), and other drugs to treat rheumatoid arthritis (adalimumab,azathioprine, certolizumab, etanercept, golimumab,英夫利昔单抗,rituximab, sarilumab, tocilizumab, and tofacitinib).
Hadlimamay also interact withwarfarinandtheophylline.
What Are Possible Side Effects of Olumiant?
Side effects of Olumiant include:
- upper respiratory tract infections (common cold,sinusinfections),
- nausea,
- cold sores (herpes simplex), and
- shingles (herpes zoster)
What Are Possible Side Effects of Hadlima?
Common side effects of Hadlima include:
- infections (e.g. upper respiratory tract, sinusitis),
- injection site reactions (redness, itching, bleeding, pain, and swelling),
- headache, and
- rash
What Is Olumiant?
Olumiant (baricitinib) is a Janus kinase (JAK) inhibitor used to treat adults with moderate to severe rheumatoid arthritis (RA) who have not responded well enough to or could not tolerate at least one medicine called atumornecrosisfactor (TNF)antagonist.
What Is Hadlima?
Hadlima(adalimumab-bwwd) is a tumor necrosis factor (TNF) blocker indicated for treatment of rheumatoid Arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA),ankylosingspondylitis(AS), adult Crohn'sdisease(CD), ulcerativecolitis(UC), andplaquepsoriasis(Ps). Hadlima is biosimilar to Olumiant (adalimumab).
What Drugs Interact With Olumiant?
Olumiant may interact with probenecid. Tell yourdoctorall medications and supplements you use.
What Drugs Interact With Hadlima?
Hadlimamay interact with abatacept, anakinra, warfarin, cyclosporine, theophylline, and live vaccines.
How Should Olumiant Be Taken?
The recommended dose of Olumiant is 2mgonce daily.
How Should Hadlima Be Taken?
The dose of Olumiant to treat adult rheumatoid arthritis and psoriatic arthritis is 50 mg once weekly with or without methotrexate (MTX). The dose of Olumiant to treat ankylosing spondylitis is 50 mg once weekly. The dose of Olumiant to treat adult plaque psoriasis is 50 mg twice weekly for 3 months, followed by 50 mg once weekly. The dose of Olumiant to treatpediatricplaque psoriasis or plaque psoriasis (patients who weigh 63 kg or more) is 50 mg once weekly.
From
Rheumatoid Arthritis Resources
Featured Centers
Health SolutionsFrom Our Sponsors
All drug information provided on RxList.com is sourced directly from drug monographs published by the U.S. Food and Drug Administration (FDA).
Any drug information published on RxList.com regarding general drug information, drug side effects, drug usage, dosage, and more are sourced from the original drug documentation found in its FDA drug monograph.
Drug information found in the drug comparisons published on RxList.com is primarily sourced from the FDA drug information. The drug comparison information found in this article does not contain any data from clinical trials with human participants or animals performed by any of the drug manufacturers comparing the drugs.
The drug comparisons information provided does not cover every potential use, warning, drug interaction, side effect, or adverse or allergic reaction. RxList.com assumes no responsibility for any healthcare administered to a person based on the information found on this site.
As drug information can and will change at any time, RxList.com makes every effort to update its drug information. Due to the time-sensitive nature of drug information, RxList.com makes no guarantees that the information provided is the most current.
Any missing drug warnings or information does not in any way guarantee the safety, effectiveness, or the lack of adverse effects of any drug. The drug information provided is intended for reference only and should not be used as a substitute for medical advice.
If you have specific questions regarding a drug’s safety, side effects, usage, warnings, etc., you should contact your doctor or pharmacist, or refer to the individual drug monograph details found on the FDA.gov or RxList.com websites for more information.
You may also report negative side effects of prescription drugs to the FDA by visiting the FDA MedWatch website or calling 1-800-FDA-1088.
Eli Lilly and Company. Olumiant Product Monograph.
https://www.olumiant.com
FDA. Hadlima Product Information.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761059s000lbl.pdf